期刊文献+

异甘草素固体脂质纳米粒中低分子肝素钠包封率的测定 被引量:1

Encapsulation efficiency determination of low molecular weight heparin in isoliquiritigenin nanoparticle
暂未订购
导出
摘要 目的测定异甘草素固体脂质纳米粒中低分子肝素钠(LMWH)的包封率。方法在Britton-Robinson(B-R)缓冲溶液中,天青A与LMWH相互作用,在662 nm处测定吸光度差值(△A),用△A对LMWH浓度进行线性回归。样品同法操作,测定LMWH的包封率。结果 LMWH的回收率在90.0%~102.5%之间,线性范围为100~1 000μg/mL(r=0.999 1),异甘草素固体脂质纳米粒中LMWH的平均包封率为35%(n=5)。结论此法操作简单、准确,适用于该制剂的质量评价。 Purpose To determine the encapsulation efficiency of low molecular weight heparin(LMWH)in isoliquiritigenin(ISL)nanoparticle.Methods In Britton-Robinson(B-R)buffer solution,Azure A chloride Salt has a maximum absorption peak at 662 nm and the absorbance reduced by the reaction with LMWH.Polynomial regression between absorbance and LMWH concentration was made.ISL nanoparticle and ultrafiltrate were treated by the similar method and absorbance was recorded.The contents of LMWH and entrapment efficiency were calculated respectively.Results Recoveries of LMWH were between 90.0%-102.5%,the linear ranges of determination of LMWH was 100-1 000 μg/mL(r=0.999 1).Average encapsulation efficiency of LMWH in ISL nanoparticle was 35%(n=5).Conclusion The method was convenient and accurate.It is suitable for the quantity control of ISL nanoparticle.
出处 《中国生化药物杂志》 CAS CSCD 北大核心 2012年第4期381-384,共4页 Chinese Journal of Biochemical Pharmaceutics
基金 甘肃省中医药科研立项课题(GZK-2008-21)
关键词 异甘草素 固体脂质纳米粒 低分子量肝素钠 天青A 纳米粒 包封率 isoliquiritigenin nanoparticle low molecular weight heparin Azure A chloride salt nanoparticle encapsulation efficiency
  • 相关文献

参考文献3

二级参考文献4

共引文献7

同被引文献22

  • 1LOIRA P C, SAPIN M A, DIAB R, et al.Low molecular weight heparin gels, based on nanoparticles, for topical delivery [J].Int J Pharm, 2012,426(1-2):256-262.
  • 2PALIWAL R, PALIWAL S R, AGRAWAL G P, et al.Chitosan nanoconstructs for improved oral delivery of low molecular weight heparin: In vitro and in vivo evaluation [J].Int J Pharm, 2012,422(1):179-184.
  • 3LEE C Y, LAI S T, SHIH C C, et al.Short-term results of catheter-directed intrathrombus thrombolysis versus anticoagulation in acute proximal deep vein thrombosis[J].J Chin Med Ass, 2013,76(5): 265-270.
  • 4HAYES P Y, ROSS B P, THOMAS B G, et al.Polycationic lipophilic-core dendrons as penetration enhancers for the oral administration of low molecular weight heparin [J].Bioorg Med Chem, 2006,14(1): 143-152.
  • 5JAVOT L, LECOMPTE T, RABISKOVA M, et al.Encapsulation of low molecular weight heparins: influence on the anti-Xa/anti-IIa ratio [J].J Controlled Release, 2009,139(1): 8-14.
  • 6OLIVEIRA S S M, OLIVEIRA F S, GAITANI C M, et al.Microparticles as a strategy for low-molecular-weight heparin delivery[J].J Pharm Sci, 2011,100(5): 1783-1792.
  • 7BAI S, AHSAN F.Synthesis and evaluation of pegylated dendrimeric nanocarrier for pulmonary delivery of low molecular weight heparin [J].Pharm Res, 2009,26(3): 539-548.
  • 8CHEN M C, WONG H S, LIN K J, et al.The characteristics, biodistribution and bioavailability of a chitosan-based nanoparticulate system for the oral delivery of heparin [J].Biomaterials, 2009,30(34): 6629-6637.
  • 9BAGRE A P, JAIN K, JAIN N K.Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment [J].Int J Pharm, 2013, 456(1): 31-40.
  • 10FUENTES M G, ALONSO M J.Chitosan-based drug nanocarriers: Where do we stand .J Controlled Release, 2012,161(2):496-504.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部